159 related articles for article (PubMed ID: 24244713)
1. Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C.
Falleti E; Cmet S; Fabris C; Fattovich G; Cussigh A; Bitetto D; Ceriani E; Lenisa I; Dissegna D; Ieluzzi D; Rostello A; Pirisi M; Toniutto P
PLoS One; 2013; 8(11):e80764. PubMed ID: 24244713
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
BMC Gastroenterol; 2017 Apr; 17(1):54. PubMed ID: 28415985
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.
Falleti E; Bitetto D; Fabris C; Fattovich G; Cussigh A; Cmet S; Ceriani E; Fornasiere E; Pasino M; Ieluzzi D; Pirisi M; Toniutto P
Hepatology; 2012 Nov; 56(5):1641-50. PubMed ID: 22610885
[TBL] [Abstract][Full Text] [Related]
4. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.
Lange CM; Bojunga J; Ramos-Lopez E; von Wagner M; Hassler A; Vermehren J; Herrmann E; Badenhoop K; Zeuzem S; Sarrazin C
J Hepatol; 2011 May; 54(5):887-93. PubMed ID: 21145801
[TBL] [Abstract][Full Text] [Related]
6. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.
Lange CM; Bibert S; Kutalik Z; Burgisser P; Cerny A; Dufour JF; Geier A; Gerlach TJ; Heim MH; Malinverni R; Negro F; Regenass S; Badenhoop K; Bojunga J; Sarrazin C; Zeuzem S; Müller T; Berg T; Bochud PY; Moradpour D;
PLoS One; 2012; 7(7):e40159. PubMed ID: 22808108
[TBL] [Abstract][Full Text] [Related]
7. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development.
Lange CM; Miki D; Ochi H; Nischalke HD; Bojunga J; Bibert S; Morikawa K; Gouttenoire J; Cerny A; Dufour JF; Gorgievski-Hrisoho M; Heim MH; Malinverni R; Müllhaupt B; Negro F; Semela D; Kutalik Z; Müller T; Spengler U; Berg T; Chayama K; Moradpour D; Bochud PY; ;
PLoS One; 2013; 8(5):e64053. PubMed ID: 23734184
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.
Petta S; Ferraro D; Cammà C; Cabibi D; Di Cristina A; Di Marco V; Di Stefano R; Grimaudo S; Mazzola A; Levrero M; Scazzone C; Craxì A
Antivir Ther; 2012; 17(5):823-31. PubMed ID: 22505587
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
12. Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C.
El-Derany MO; Hamdy NM; Al-Ansari NL; El-Mesallamy HO
BMC Gastroenterol; 2016 Feb; 16():19. PubMed ID: 26911666
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.
Lim YP; Peng CY; Liao WL; Hung DZ; Tien N; Chen CY; Chang SY; Chang CY; Tsai FJ; Wan L
J Med Virol; 2013 Jul; 85(7):1206-14. PubMed ID: 23918539
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
Arai T; Atsukawa M; Tsubota A; Kondo C; Shimada N; Abe H; Itokawa N; Nakagawa A; Okubo T; Aizawa Y; Iwakiri K
J Med Virol; 2015 Nov; 87(11):1904-12. PubMed ID: 25964133
[TBL] [Abstract][Full Text] [Related]
15. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.
García-Martín E; Agúndez JA; Maestro ML; Suárez A; Vidaurreta M; Martínez C; Fernández-Pérez C; Ortega L; Ladero JM
PLoS One; 2013; 8(9):e74764. PubMed ID: 24073221
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D pathway gene variants and HCV-2/3 therapy outcomes.
Cusato J; Allegra S; Boglione L; De Nicolò A; Baietto L; Cariti G; Di Perri G; D'Avolio A
Antivir Ther; 2015; 20(3):335-41. PubMed ID: 25279449
[TBL] [Abstract][Full Text] [Related]
17. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2R1, CYP27A1 and CYP27B1 genetic polymorphisms controlling vitamin D metabolism on susceptibility to hepatitis C virus infection in a high-risk Chinese population.
Yang JJ; Fan HZ; Tian T; Wu MP; Xie CN; Huang P; Yu RB; Yi HG; Zhang Y; Wang J
Arch Virol; 2019 Dec; 164(12):2909-2918. PubMed ID: 31520221
[TBL] [Abstract][Full Text] [Related]
19. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
